Discovering AP3B1: A GPCR-Melanoma Potential Drug Target (G8546)

Target Name: AP3B1

NCBI ID: G8546

AP3B1

Discovering AP3B1: A GPCR-Melanoma Potential Drug Target

AP3B1 (beta-3A) is a protein that is expressed in the brain and is involved in the regulation of pain, anxiety, and mood. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a key role in cellular signaling.

The discovery and characterization of AP3B1 was made by a team of researchers at the University of California, San Diego (UCSD). The researchers identified AP3B1 as a potential drug target (or biomarker) because of its involvement in the regulation of pain, anxiety, and mood. They found that blocking the activity of AP3B1 reduced the sensitivity to pain in animals and improved the behavior of animals that were experiencing anxiety or depression.

The researchers also found that blocking the activity of AP3B1 improved the activity of a neurotransmitter called dopamine, which is involved in mood regulation. They also found that blocking the activity of AP3B1 reduced the activity of a protein called TrkB, which is involved in the regulation of pain.

The potential drug target (or biomarker) of AP3B1 is the GPCR family of proteins, which are involved in cellular signaling. GPCR family proteins are involved in a wide range of cellular processes, including sensory perception, neurotransmission, and hormone signaling. They are also involved in the regulation of pain, anxiety, and mood.

The GPCR family of proteins is a large and diverse family that is expressed in many different tissues and organs. They are involved in the regulation of a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. They are also involved in the regulation of pain, anxiety, and mood.

AP3B1 is a member of the GPCR family of proteins and is expressed in the brain. It is involved in the regulation of pain, anxiety, and mood. The discovery and characterization of AP3B1 as a potential drug target (or biomarker) has the potential to lead to new treatments for a wide range of psychiatric and neurological disorders.

Protein Name: Adaptor Related Protein Complex 3 Subunit Beta 1

Functions: Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. AP-3 appears to be involved in the sorting of a subset of transmembrane proteins targeted to lysosomes and lysosome-related organelles. In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals

The "AP3B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AP3B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets